Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1007862/full |
| _version_ | 1811283399630913536 |
|---|---|
| author | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi |
| author_facet | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi |
| author_sort | Yin Yang |
| collection | DOAJ |
| first_indexed | 2024-04-13T02:12:03Z |
| format | Article |
| id | doaj.art-d945687fc1ba4b6ca0be33f590f5a185 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T02:12:03Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d945687fc1ba4b6ca0be33f590f5a1852022-12-22T03:07:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.10078621007862Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysisYin Yang0Jianyang Wang1Wenqing Wang2Tao Zhang3Jingjing Zhao4Yu Wang5Yexiong Li6Luhua Wang7Nan Bi8Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinahttps://www.frontiersin.org/articles/10.3389/fonc.2022.1007862/fullLimited-stage small-cell lung cancersurrogate endpointoverall survivalprogression-free survivaltime to progressionchemoradiotherapy |
| spellingShingle | Yin Yang Jianyang Wang Wenqing Wang Tao Zhang Jingjing Zhao Yu Wang Yexiong Li Luhua Wang Nan Bi Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis Frontiers in Oncology Limited-stage small-cell lung cancer surrogate endpoint overall survival progression-free survival time to progression chemoradiotherapy |
| title | Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis |
| title_full | Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis |
| title_fullStr | Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis |
| title_full_unstemmed | Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis |
| title_short | Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis |
| title_sort | corrigendum progression free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited stage small cell lung cancer a systematic review and meta analysis |
| topic | Limited-stage small-cell lung cancer surrogate endpoint overall survival progression-free survival time to progression chemoradiotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1007862/full |
| work_keys_str_mv | AT yinyang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT jianyangwang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT wenqingwang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT taozhang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT jingjingzhao corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT yuwang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT yexiongli corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT luhuawang corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis AT nanbi corrigendumprogressionfreesurvivalandtimetoprogressionaspotentialsurrogateendpointsforoverallsurvivalinchemoradiotherapytrialsinlimitedstagesmallcelllungcancerasystematicreviewandmetaanalysis |